Ligand Pharma (LGND) PT Raised to $335 at Benchmark as XOMA Royalty Cash Acquisition Completed
Tweet Send to a Friend
(Updated - July 16, 2026 9:56 AM EDT)
Benchmark analyst Robert Wasserman raised the price target on Ligand Pharma ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Benchmark analyst Robert Wasserman raised the price target on Ligand Pharma ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
